IMUNON, Inc. announced on February 26, 2025, new safety and immunogenicity data from its first Phase 1 proof-of-concept clinical trial of IMNN-101, a COVID-19 booster vaccine candidate based on its proprietary PlaCCine technology platform. The study, conducted in 24 healthy volunteers, showed IMNN-101 was safe and well-tolerated with no serious adverse effects.
IMNN-101 induced a persistent 2- to 4-fold increase in serum neutralizing antibody (NAb) titers from baseline through Week 4, demonstrating cross-reactivity against the Omicron XBB1.5 variant and newer variants. The immune response was observed in participants who were previously vaccinated against the Omicron XBB1.5 variant.
These results provide strong evidence of vaccine immunogenicity in humans, consistent with preclinical data showing over 95% protection in non-human primates. IMUNON plans to seek potential partners for further development of the PlaCCine platform, leveraging its robust immunogenicity, expected durability, and manufacturing advantages.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.